AIDS is a challenge to mankind. Widespread use of cART changed HIV
from a progressive illness with a lethal prognosis into a chronic controlled disease with
some side-effects. There is a problem of latent infection or viral reservoir(s), which is
unaffected by ART and is not recognized by the immune system. Many researches
have concentrated on reducing/disrupting the latent viral reservoir(s) to get rid of HIV.
Mucosal surfaces are the entry point and the major regions of HIV-replication. HIV is
associated with dramatic loss of gastrointestinal Th17 cells, high mucosal permeability,
and chronic inflammation. Effective treatments or prophylaxis at the mucosal level are
much needed. Understanding the interplay between microbiota and HIV is important
for development successful strategies for HIV/AIDS prevention, treatment and care.
Increasing evidence indicate that microbiota can play an important role in HIV
transmission and pathogenesis. A new powerful probiotic product (PP) was developed.
PP stimulates growth of symbiotic microflora and has a very broad spectrum of antimicrobial
activity. PP boosts the immune system. The strongest stimulation of mucosal
immune system occurred when PP was administered directly at a mucosal surface.
Various routes of PP administration are discussed. PP can improve function of
cardiovascular system and cognitive function in HIV/AIDS patients. PP provided relief
from opportunistic infections and improved immunological status in HIV/AIDS
individuals. It is expected that PP can be used as supplemental therapy to cART.
Keywords: AIDS, Antiretroviral therapy, Cytotoxic T lymphocytes, Gut
permeability, HIV, HIV-1, HIV-associated neurocognitive disorders, Human
immunodeficiency virus, Inflammation, Latency, Latency reversing agent, LRA,
MALT, Microbiota, Mucosal immunology, Mucus-associated lymphoid tissue,
Neurotrophic factors, Non-toxicity, Opportunistic infection, Probiotics, Th17, Viral reactivation, Viral reservoirs.
